Biopharma & regulatory strategy for the GCC's most ambitious companies.
I help biopharma and biotech companies, investors, and health authorities advance biologics from molecule to market in Saudi Arabia and the GCC — combining biomanufacturing science, SFDA regulatory experience, and commercialization strategy under one roof.
Credentials
Former SFDA Biotech Strategic Advisor; current Scientific Committee member at SFDA
Regulator Advisory
2022
VC University - Life Science Track
2022
Independent technical due diligence on biologic assets, regulatory pathway risk assessment, and market access analysis for biotech investments in US and Europe. Combines deep scientific expertise with venture capital methodology, PitchBook practitioner.
Three years assessing biopharmaceutical and biotech inventions for US patent filing, in partnership with US legal counsel | Entrepreneurship Institute, KSU.
Patent Assessment Lead
2023
Drug R&D Society
2024
Founder & Chairman
Geneva International Exhibition of Inventions — novel therapeutic for MERS infection.
+3 U.S. patents
Medals & Patents
2025-26
In the Press
Featured among Saudi researchers in biotechnology and drug development, with recognition of three US patents (including antimicrobial peptides effective against MRSA) and the 2026 Geneva Silver Medal for a novel MERS therapeutic — coverage tied to participation in King Saud University's Creativity and Innovation Exhibition.
2026
2025
Featured among King Saud University's award winners at the 51st Geneva International Exhibition of Inventions 2026, including the Silver Medal for a novel MERS therapeutic
2026
Convening the SFDA, industry partners, and academia to advance integration between biomanufacturing,
Specialized advisory across regulatory strategy, biomanufacturing, investor diligence, and AI-driven protein design. Saudi Arabia, the GCC, and US–GCC cross-border engagements
Our Services
For Pharma & Biotech Executives
GCC market entry, SFDA pathway design, biosimilar strategy, biomanufacturing localization, and Vision 2030 alignment. I help global pharma and biotech companies translate science into approved, locally produced products.
US–GCC Biotech Bridge
For US biotech companies seeking GCC market entry, and GCC stakeholders pursuing US biotech partnerships, licensing, or investment. Through a network of US-based biotech specialists, I provide cross-border regulatory navigation and deal facilitation.
For Investors & Due Diligence
Technical and regulatory due diligence on biologics assets, IP strength evaluation, and GCC commercialization viability — combining the scientist's depth with the investor's lens.
AI-Driven Biotech Engineering
Computational design and optimization of therapeutic proteins using a proprietary AI platform. The model predicts stabilizing mutations in monoclonal antibodies, therapeutic proteins, and peptide-based drugs — validated across benchmark proteins with strong predictive accuracy. Available to biotech companies and academic groups seeking to de-risk protein design, improve developability, or optimize biosimilar candidates.
Founder, ConformaBio
For Regulators & Policymakers
Biosimilar adoption strategy, biologics formulary decisions, guideline development, biomanufacturing standards, and capacity-building programs aligned with national pharmaceutical localization goals.
Selected Research
MERS-CoV Protease Inhibitor Program (2020–present)
A sustained research program identifying small-molecule inhibitors of the MERS-CoV papain-like protease — a high-priority therapeutic target for a pathogen with a ~35% case-fatality rate and no approved antivirals. To date, five chemically diverse inhibitors have been characterized across multiple binding sites: doxorubicin, sunitinib, sinapic acid, erythromycin, and fisetin. The fisetin work received the 2026 Geneva Silver Medal and is the subject of US Patent 12,208,082 B1.
AI-Driven Protein Engineering
Development of computational tools for therapeutic protein design — including a proprietary AI model for predicting stabilizing mutations, and integration of state-of-the-art AI methods into experimental drug discovery workflows.
Biosimilar Development
Active program developing a cost-reduced expression strategy for insulin glargine biosimilar. Currently expressing the proinsulin precursor — a key milestone toward GCC biosimilar localization.
Let's start a conversation
Every engagement is unique. Whether you're a pharma executive exploring GCC market entry, an investor conducting due diligence on a biologic asset, or a health authority shaping policy, I'm available to discuss how I can help. Send a message or schedule an introductory call.